1. Home
  2. BFST vs EVO Comparison

BFST vs EVO Comparison

Compare BFST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Business First Bancshares Inc.

BFST

Business First Bancshares Inc.

HOLD

Current Price

$27.98

Market Cap

877.1M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.01

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFST
EVO
Founded
2006
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
877.1M
934.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
BFST
EVO
Price
$27.98
$3.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$32.75
$7.00
AVG Volume (30 Days)
141.8K
85.0K
Earning Date
04-27-2026
04-08-2026
Dividend Yield
2.23%
N/A
EPS Growth
23.45
N/A
EPS
0.68
N/A
Revenue
$10,704,000.00
N/A
Revenue This Year
$22.71
$1.37
Revenue Next Year
$5.02
$10.05
P/E Ratio
$41.16
N/A
Revenue Growth
1.20
N/A
52 Week Low
$22.56
$2.31
52 Week High
$30.32
$4.48

Technical Indicators

Market Signals
Indicator
BFST
EVO
Relative Strength Index (RSI) 55.01 53.04
Support Level $26.73 $2.88
Resistance Level $28.74 $3.36
Average True Range (ATR) 0.53 0.09
MACD 0.08 -0.01
Stochastic Oscillator 75.72 54.34

Price Performance

Historical Comparison
BFST
EVO

About BFST Business First Bancshares Inc.

Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: